1.71
전일 마감가:
$1.82
열려 있는:
$1.83
하루 거래량:
1.72M
Relative Volume:
0.87
시가총액:
$535.16M
수익:
$6.23M
순이익/손실:
$-95.90M
주가수익비율:
-4.3846
EPS:
-0.39
순현금흐름:
$-68.47M
1주 성능:
+2.40%
1개월 성능:
-1.16%
6개월 성능:
+85.15%
1년 성능:
+21.71%
Precigen Inc Stock (PGEN) Company Profile
명칭
Precigen Inc
전화
301-556-9900
주소
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
PGEN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PGEN
Precigen Inc
|
1.71 | 535.16M | 6.23M | -95.90M | -68.47M | -0.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
605.52 | 36.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 36.37B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-03-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2023-05-23 | 개시 | JP Morgan | Neutral |
2022-11-18 | 개시 | Cantor Fitzgerald | Overweight |
2021-02-25 | 개시 | Stifel | Buy |
2021-02-22 | 개시 | Wells Fargo | Overweight |
2021-02-18 | 개시 | B. Riley Securities | Buy |
2020-05-08 | 개시 | H.C. Wainwright | Buy |
모두보기
Precigen Inc 주식(PGEN)의 최신 뉴스
Precigen, Inc. (NASDAQ:PGEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Cantor Fitzgerald raises Precigen stock target to $5 By Investing.com - Investing.com Australia
10 Hot Biotech Stocks Under $5 - Insider Monkey
Precigen’s Earnings Call: Positive Outlook Amid Challenges - TipRanks
Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Exp - GuruFocus.com
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch By Investing.com - Investing.com South Africa
Analysts Are Bullish on Precigen Stock (PGEN) Amid Positive Pipeline Developments - Markets Insider
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Precigen, Inc. f/k/a Intrexon Corporation Investors of Important Deadline in Securities Class Action First Filed by the Firm – PGEN, XON - Business Wire
Stifel maintains Precigen stock Buy rating with $7 target By Investing.com - Investing.com South Africa
Precigen’s SWOT analysis: biotech firm’s stock poised for potential launch - Investing.com India
Expert Outlook: Precigen Through The Eyes Of 4 Analysts - Benzinga
Cantor Fitzgerald raises Precigen stock target to $5 - Investing.com
Stifel maintains Precigen stock Buy rating with $7 target - Investing.com
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates buy on Precigen stock, maintains $6 target - Investing.com
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises By Investing.com - Investing.com South Africa
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance
Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing Opportunities - GuruFocus.com
Precigen earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Precigen Reports Progress and Financial Results for 2024 - TipRanks
Precigen Reports Full Year 2024 Financial Results and Business Updates - The Malaysian Reserve
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - MSN
Earnings call transcript: Precigen Q4 2024 sees net loss, stock rises - Investing.com Canada
Precigen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Precigen Inc Reports Q4 Net Loss of $(0.47) Per Share, Revenue o - GuruFocus.com
PRECIGEN, INC. SEC 10-K Report - TradingView
How Do Things Look For Precigen Inc (NASDAQ: PGEN) In The Short-Term? - Stocks Register
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Precigen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Business Wire
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Analysts Set Precigen, Inc. (NASDAQ:PGEN) Price Target at $7.00 - MarketBeat
Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th - Quantisnow
Precigen Gene Therapy Pioneer Reveals 2024 Performance: Key Financial Results Coming March 19 - StockTitan
Exploring High Growth Tech Stocks In The US Market - Simply Wall St
Precigen, Inc. (NASDAQ:PGEN) Stock Holdings Increased by Rhumbline Advisers - Defense World
Precigen (PGEN) Projected to Post Earnings on Tuesday - Defense World
Is Precigen Inc’s (NASDAQ:PGEN) Stock On The Decline? - Stocks Register
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Insider Monkey
Precigen (NASDAQ:PGEN) Shares Gap UpWhat's Next? - MarketBeat
Precigen (NASDAQ:PGEN) Shares Up 7.7%Time to Buy? - MarketBeat
Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha
FDA advances Precigen’s gene therapy for respiratory disease By Investing.com - Investing.com Australia
FDA Accepts for Review Precigen RRP Gene Therapy Candidate - Genetic Engineering & Biotechnology News
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com Australia
FDA Accepts BLA for Precigen’s Recurrent Respiratory Papillomatosis Gene Therapy PRGN-2012 With Priority Review - CGTLive™
Decades in, this Germantown biopharma is on the cusp of bringing its first product to market - The Business Journals
Precigen gets FDA Priority Review for its respiratory tract tumor treatment - MSN
Stifel maintains Precigen stock Buy rating, $7 target post-FDA update By Investing.com - Investing.com South Africa
Precigen Says FDA Accepts for Priority Review Application for Recurrent Respiratory Papillomatosis Treatment - Marketscreener.com
Precigen Inc (PGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):